Skip to Content

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Pemigatinib – a oral FGFR1-3 inhibitor has shown efficacy and safety in patients with advanced/metastatic cholangiocarcinoma publish in the Lancet Oncol 2020. In this MEDtalk Abou-Alfa K. Ghassan present the update FIGHT-202 study, where overall survival for responders was more than twice as long vs for non-responders

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top